FDA / Federal Register Notice: Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry; Availability
New FDA guidance impacts sourcing for compounding in med spas.
What changed & why it matters
Med Spa Radar recorded a Federal Register notice at the federal level, dated January 7, 2025, in the GLP-1 Compounding category.
Federal Register activity is where federal compounding policy is actually written — proposed rules, comment periods, and clinical-need determinations that decide which bulk substances may be compounded under sections 503A and 503B.
- Type
- Federal Register
- Jurisdiction
- Federal
- Category
- GLP-1 Compounding
- Recorded
- January 7, 2025
What this means for your specific practice — the exact step to take, the deadline to calendar, or the supplier detail to check — is in the member "what to do" below. This page is the free record of what changed and why it matters.
What to do
Free weekly Brief
Get the changes that matter in plain English, every week — and be alerted when the rules move. No charge.
Members get the full “what to do” on every alert — in real time, for your states. Become a member →
Federal Register · primary source ↗
Related alerts
- FDA recall (Class II): Semaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, Ks 66061,…
- FDA recall (Class II): Semaglutide, 2.5 mg/mL injection, 2 mL., Boothwyn Pharmacy
- FDA recall (Class II): Tirzepatide + Niacinamide 16.6 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, …
- FDA recall (Class II): Tirzepatide Injections, 30mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewo…
- FDA recall (Class II): Wegovy (Semaglutide) Injection, 0.5 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880…
- FDA recall (Class II): Wegovy (Semaglutide) injection, 2.4 mg/0.75 mL, 4 Single-Dose Prefilled Pens per Carton, For Subcutaneous Use Only, Rx …
Monitoring, not legal advice.